ODTX
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. (ODTX) has 8 SEC Form 4 filings (32 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: May 12, 2026.
Insiders have net bought $50.3M over the trailing 6 months. The largest single insider purchase in this window was $20.0M by Director Dimension Capital II, L.P. on May 8, 2026.
- Industry:Biotechnology
- CEO:Gary D. Glick
- Employees:100
- HQ:Boston, MA, US
- IPO:2026-05-08
Insider Buying
$50.3M
reported purchases (SEC code P)
Insider Selling
$32K
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$831.4M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Dimension Capital II, L.P.First filing | Director | Purchase | 1,111,111 | $20.0M | May 12 | SEC ↗ |
| 10% Owner | Sale | 1,780 | $32K | May 12 | SEC ↗ | |
| 10% Owner | Purchase | 555,555 | $10.0M | May 12 | SEC ↗ | |
LEIDEN JEFFREY MFirst in 5 months | Director | Purchase | 5,000 | $100K | May 12 | SEC ↗ |
Haas JasonFirst filing | Chief Financial Officer | Purchase | 1,000 | $20K | May 12 | SEC ↗ |
Li Nan (LN)First filing | Director | Purchase | 1,111,111 | $20.0M | May 12 | SEC ↗ |
Chu ShelleyFirst filing | Director | Purchase | 11,111 | $200K | May 12 | SEC ↗ |
Related companies
Odyssey Therapeutics, Inc. is in the Healthcare sector.